Who Paid My Doc
Gregory Niemer
Rheumatology Summerville, SC Medical Doctor
NPI 1356449367 CMS profile 333280
2001 2Nd Ave Ste 201, Summerville, SC 29486
General payments
$2,868,309
Research payments
$0
Ownership & investment interest
$8,751,675
Research they led as principal investigator
$284,042
Through program year 2025, Gregory Niemer of Summerville, SC is reported in the CMS Open Payments database as having received $2,868,309 across 998 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $284,042 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $8,751,675 across 6 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,291,306 | 153 | |
| 2024 | General | $126,049 | 158 | |
| 2023 | General | $629,219 | 128 | |
| 2022 | General | $458,616 | 150 | |
| 2021 | General | $207,692 | 145 | |
| 2020 | General | $101,318 | 88 | |
| 2019 | General | $54,110 | 176 | |
| 2025 | Ownership | $1,275,000 | 1 | |
| 2024 | Ownership | $2,303,679 | 1 | |
| 2023 | Ownership | $2,684,879 | 1 | |
| 2022 | Ownership | $1,838,986 | 1 | |
| 2021 | Ownership | $627,131 | 1 | |
| 2019 | Ownership | $22,000 | 1 |
Beside peers
- Gregory Niemer
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Gregory Niemer were reported at $1,291,306. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Gregory Niemer | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $54,110 | $744 | $153–$2,687 | $163 |
| 2020 | $101,318 | $462 | $98–$2,027 | $114 |
| 2021 | $207,692 | $531 | $101–$2,153 | $132 |
| 2022 | $458,616 | $627 | $125–$2,303 | $149 |
| 2023 | $629,219 | $741 | $145–$2,524 | $160 |
| 2024 | $126,049 | $830 | $166–$2,660 | $164 |
| 2025 | $1,291,306 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 47 drugsPart D claims
2,761
Drug cost
$1,237,890
Branded share of claims
22.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Enbrel Sureclick Etanercept | Brand | 35 | $307,115 | |
| Tremfya Guselkumab | Brand | 13 | $182,338 | |
| Rinvoq Upadacitinib | Brand | 22 | $168,189 | |
| Orencia Clickject Abatacept | Brand | 28 | $167,483 | |
| Cimzia (2 Pack) Certolizumab Pegol | Brand | 20 | $113,647 | |
| Cosentyx (2 Syringes) Secukinumab | Brand | 13 | $93,777 | |
| Benlysta Belimumab | Brand | 19 | $81,096 | |
| Otezla Apremilast | Brand | 13 | $47,427 | |
| Hydroxychloroquine Sulfate | Generic | 572 | $21,391 | |
| Methotrexate Methotrexate Sodium | Brand | 357 | $7,727 |
The 10 drugs with the highest cost, of 47 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 72 billing codesPaid by Medicare
$1,460,300
Medicare patients
698
Services billed
112,694
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Osteoporosis | 40% | |
| Diabetes | 26% | |
| Chronic kidney disease | 26% | |
| Depression | 25% | |
| Ischemic heart disease | 22% | |
| Atrial fibrillation | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 | Office | 60 | 10,525 | $349,015 |
| Injection, golimumab, 1 mg, for intravenous use J1602 | Office | 74 | 22,860 | $198,928 |
| Injection, tocilizumab, 1 mg J3262 | Office | 25 | 31,560 | $148,035 |
| Injection, rituximab, 10 mg J9312 | Office | 11 | 1,150 | $70,377 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 | Office | 18 | 19,000 | $68,180 |
| Injection, romosozumab-aqqg, 1 mg J3111 | Office | 17 | 7,350 | $62,532 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg Q5104 | Office | 17 | 2,010 | $46,763 |
| Injection, denosumab, 1 mg J0897 | Office | 29 | 1,920 | $39,554 |
| Injection, infliximab, excludes biosimilar, 10 mg J1745 | Office | 19 | 1,480 | $27,431 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 20 | 775 | $180 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 28 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| RINVOQ |
|
$6,191 | 22 | — |
| TREMFYA |
|
$600 | 13 | — |
| OCTAGAM IMMUNE GLOBULIN (HUMAN) |
|
$437 | — | — |
| COSENTYX |
|
$298 | 13 | — |
| KRYSTEXXA |
|
$236 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 28 with PatronRecords
998 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Rheumatology in South Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in South Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.